Citations

Showing 10 of 108104 citations.

Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
Charalampous, Charalampos , Goel, Utkarsh , Broski, Stephen M. , Dingli, David , Kapoor, Prashant , Gertz, Morie A. , Lacy, Martha Q. , Hayman, Suzanne R. , Buadi, Francis K. , Hwa, Yi L. , Lin, Yi , Kourelis, Taxiarchis , Warsame, Rahma , Fonder, Amie , Hobbs, Miriam, Binder, Moritz , Kyle, Robert A. , Kumar, Shaji , Dispenzieri, Angela , Buadi, Francis K , Leung, Nelson , Kourelis, Taxiarchis , Warsame, Rahma , Fonder, Amie , Binder, Moritz , Kumar, Shaji K , Gertz, Morie A , Dingli, David , Broski, Stephen M , Lin, Yi , Dispenzieri, Angela , Leung, Nelson , Gonsalves, Wilson I. , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | March 2, 2022 | Volume: 6 | Issue: 9 | Pages: 2763-2772

10.1182/bloodadvances.2022007052 | PMID 35235951 Get It

Abstract Multiple myeloma (MM) is a plasma cell malignancy that is characterized by diverse clinical presentations. Although biochemical assessment of disease activity is commonly used to monitor treatment response, findings on magnetic resonance imaging and positron emission tomography (PET)/computed tomography (CT), among other imaging modalities, have proven to harbor prognostic value. We sought to corroborate these findings by examining the prognostic significance of fluorodeoxyglucose PET/CT scanning in the setting of newly diagnosed MM. We retrospectively analyzed 195 patients with a PET/CT available at diagnosis and at 6 months posttreatment to examine their value as an adjuvant metric to conventional hematologic responses in terms of time to next treatment (TTNT) and overall survival (OS). The median TTNT and OS for the entire cohort were 24.6 months (95% confidence interval [CI], 20.4-29.1) and 79 months (95% CI, 63.1-119.1), respectively. When comparing PET/CT negative (−) with PET/CT positive (+) patients, we found significantly prolonged median TTNT (55.2 vs 17.8 months, P < .0001) and OS (unreached vs 60.8 months, P < .0001) in the former group. We then examined the additive value of PET/CT on the hematologic response achieved at 6 months and found that PET/CT (−) is associated with significantly increased median TTNT and OS for the very good partial response (VGPR) group and the less than VGPR group. Importantly, PET/CT retained prognostic significance after adjusting for multiple other predictive variables. We conclude that a PET/CT (−) at 6 months confers a significant prognostic advantage for patients with newly diagnosed MM and adds significant value to the hematologic response assessment.
Engaging and Supporting Care Partners of Persons With Dementia in Health-Care Delivery: Results From a National Consensus Conference
Riffin, Catherine , Griffin, Joan M. , Brody, Lilla , Wolff, Jennifer L. , Adelman, Ronald D., Bangerter, Lauren R. , Starks, Steven , Falzarano, Francesca , Villanigro-Santiago, Martha, Veney, Loretta, Falzarano, Francesca , Griffin, Joan M , Pillemer, Karl Andrew , Czaja, Sara J.

Mayo Clinic

Public Policy & Aging Report | March 2, 2022 | Volume: 32 | Issue: 2 | Pages: 58-65

10.1093/ppar/prac004 | PMID 35607366 Get It

Using advanced racial and ethnic identity demographics to improve surveillance of work‐related conditions in an occupational clinic setting
Montoya‐Barthelemy, Andre , Leniek, Karyn , Bannister, Emily L., Rushing, Marcus D. , Abrar, Fozia A., Baumann, Tobias E., Manly, Madeleine, Wilhelm, Jonathan , Niece, Ashley D., Riester, Scott M. , Sellman, Jonathan, Anderson, Paul J., Bovard, Ralph , Pronk, Nicolas P., McKinney, Zeke J. , Montoya-Barthelemy, Andre G , Riester, Scott , Kim, Hyun , McKinney, Zeke J , Wilhelm, Jonathan, Desai, Jay

Mayo Clinic

American Journal of Industrial Medicine | March 2, 2022 | Volume: 65 | Issue: 5 | Pages: 357-370

10.1002/ajim.23332 | PMID 35235683 Get It

AbstractBackgroundAlthough racial and ethnic identities are associated with a multitude of disparate medical outcomes, surveillance of these subpopulations in the occupational clinic setting could benefit enormously from a more detailed and nuanced recognition of racial and ethnic identity.MethodsThe research group designed a brief questionnaire to capture several dimensions of this identity and collected data from patients seen for work‐related conditions in four occupational medicine clinics from May 2019 through March 2020. Responses were used to calculate the sensitivity and specificity of extant racial/ethnic identity data within our electronic health records system, and were compared to participants' self‐reported industry and occupation, coded according to North American Industry Classification System and Standard Occupational Classification System listings.ResultsOur questionnaire permitted collection of data that defined our patients' specific racial/ethnic identity with far greater detail, identified patients with multiple ethnic identities, and elicited their preferred language. Response rate was excellent (94.2%, n = 773). Non‐White participants frequently selected a racial/ethnic subcategory (78.1%–92.2%). Using our race/ethnicity data as a referent, the electronic health record (EHR) had a high specificity (>87.1%), widely variable sensitivity (11.8%–82.2%), and poorer response rates (75.1% for race, 82.5% for ethnicity, as compared to 93.8% with our questionnaire). Additional analyses revealed some industries and occupations disproportionately populated by patients of particular racial/ethnic identities.ConclusionsOur project demonstrates the usefulness of a questionnaire which more effectively identifies racial/ethnic subpopulations in an occupational medicine clinic, permitting far more detailed characterization of their occupations, industries, and diagnoses.
Chronic Pancreatitis
Vege, Santhi Swaroop, Chari, Suresh T. , Chari, Suresh T , Vege, Santhi Swaroop

Mayo Clinic

New England Journal of Medicine | March 2, 2022 | Volume: 386 | Issue: 9 | Pages: 869-878

10.1056/nejmcp1809396 | PMID 35235728 Get It

Aneurysmal bone cyst on top of fibro-osseous lesion of the ethmoid sinus with orbital and intracranial extension in a child
Elsayed, Ayman A., Mohamed, Rawia Mubarak , Devine, J.C. , ElBadawey, Mohamed Reda, Abdelsamad, H. S. S., Sajid, Sameeha, Mansour, Zeenah Ryad, Elsayed, Ayman Ahmed , Mohamed, Rawia Mubarak Hamad, Devine, John Charles, Wasserberg, Jonathan, Wasserberg, Jonathan

Mayo Clinic

BJR|case reports | March 2, 2022 | Volume: 8 | Issue: 3 | Pages: No page available

10.1259/bjrcr.20210246 | PMID 36101731 Get It

Objective Aneurysmal bone cysts (ABCs) rarely involve the cranium. We report a case arising in the ethmoid sinus with orbital and intracranial invasion. Imaging suggested an associated fibro-osseous lesion. The lesion was completely resected. Histology confirmed the imaging diagnosis of ABC on top of an ossifying fibroma. A multidisciplinary approach is essential for optimal surgical outcomes. Methods We report a case of an 8-year-old boy with a 5 week history of painless, increasing prominence of the left eye. Clinical examination revealed non-pulsatile left proptosis. Visual acuity and ocular movements were normal. CT and MRI scans of the maxillofacial regions showed a large space-occupying lesion involving the left ethmoid air cells with left orbital and left inferior frontal intracranial extension. Multiple fluid levels with blood products were seen. Areas of the bony component of the lesion showed ground-glass density on CT. Imaging was consistent with an ABC with an underlying fibro-osseous lesion; probably fibrous dysplasia which was confirmed after surgical removal of the lesion. A multidisciplinary team of maxillofacial, neurosusugery and ENT surgeons performed the surgery. Results ABC arising from an osseous fibroma of the skull is rare. Total resection can be achieved with a multidisciplinary surgical approach. Post-operative histology confirmed by the imaging findings.
Modeling the Cost of Teleneonatology from the Health System Perspective
Thao, Viengneesee , Dholakia, Ruchita, Kreofsky, Beth L. , Colby, Christopher E. , Demaerschalk, Bart M. , Fang, Jennifer L. , Moriarty, James P. , Demaerschalk, Bart M , Borah, Bijan J.

Mayo Clinic

Telemedicine and e-Health | March 2, 2022 | Volume: 28 | Issue: 10 | Pages: 1464-1469

10.1089/tmj.2021.0527 | PMID 35235430 Get It

Introduction: Teleneonatology (TN) allows remote neonatologists to provide real-time audio-video telemedicine support to community hospitals when neonates require advanced resuscitation or critical care. Currently, there are no published economic evaluations of U.S. TN programs. Objective: To evaluate the cost of TN from the perspective of the health care system. Methods: We constructed a decision tree comparing TN to usual care for neonates born in hospitals without a neonatal intensive care unit (NICU) who require consultation. Our outcome of interest was total cost per patient, which included the incremental cost of a TN program, the cost of medical transport, and the cost of NICU or non-NICU hospitalization. We performed threshold sensitivity analyses where we varied each parameter to determine whether the base-case finding reverted. Results: For neonates requiring consultation after birth in a hospital without a NICU, TN was less costly ($16,878) than usual care ($28,047), representing a cost-savings of $11,168 per patient. Sensitivity analyses demonstrated that at least one of the following conditions would need to be met for TN to no longer be cost saving compared to usual care: transfer rate with usual care <12% (base-case = 82%), TN reducing the odds of transfer by <8% (base-case = 52%), or TN cost exceeding $12,989 per patient (base-case = $1,821 per patient). Conclusions: Economic modeling from the health system perspective demonstrated that TN was cost saving compared to usual care for neonates requiring consultation following delivery in a non-NICU hospital. Understanding the cost savings associated with TN may influence organizational decisions regarding implementation, diffusion, and retention of these programs.
Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease
Wang, Xiaofang, Jiang, Li, Thao, Ka, Sussman, Caroline R. , LaBranche, Timothy, Palmer, Michael, Harris, Peter C. , McKnight, G. Stanley, Hoeflich, Klaus P., Schalm, Stefanie, Torres, Vicente E., Torres, Vicente E. , Harris, Peter C , Torres, Vicente E , Wang, Xiaofang, Jiang, Li, Thao, Ka, Sussman, Caroline R. , LaBranche, Timothy, Palmer, Michael, McKnight, G. Stanley, Hoeflich, Klaus P., Schalm, Stefanie, Torres, Vicente E.

Mayo Clinic

Journal of the American Society of Nephrology | March 2, 2022 | Volume: 33 | Issue: 6 | Pages: 1087-1104

10.1681/asn.2021081125 | PMID 35236775 Get It

Significance Statement The only treatment approved for PKD inhibits production of cAMP, the main PKA activator. It is only partially effective, likely because side effects restrict dosing and because other sources of cAMP and mechanisms of cAMP-independent PKA activation exist. Which PKA isozyme(s) promotes PKD is uncertain and selective PKA inhibitors usable in vivo have not been available. Experiments in a mouse model show PKA-I is the main PKA isozyme promoting cystogenesis and that constitutive PKA-I downregulation and a novel, highly selective PKA inhibitor ameliorate PKD. The dose of PKA inhibitor used had no detectable adverse effects. This information provides a strong rationale for a strategy that may be more effective, or substantially increase the efficacy of the currently approved treatment. Background Upregulation of cAMP-dependent and cAMP-independent PKA signaling is thought to promote cystogenesis in polycystic kidney disease (PKD). PKA-I regulatory subunit RI α is increased in kidneys of orthologous mouse models. Kidney-specific knockout of RI α upregulates PKA activity, induces cystic disease in wild-type mice, and aggravates it in Pkd1 RC/RC mice. Methods PKA-I activation or inhibition was compared with EPAC activation or PKA-II inhibition using Pkd1 RC/RC metanephric organ cultures. The effect of constitutive PKA (preferentially PKA-I) downregulation in vivo was ascertained by kidney-specific expression of a dominant negative RIαB allele in Pkd1 RC/RC mice obtained by crossing Prkar1α R1αB/WT , Pkd1RC/RC , and Pkhd1- Cre mice (C57BL/6 background). The effect of pharmacologic PKA inhibition using a novel, selective PRKACA inhibitor (BLU2864) was tested in mIMCD3 3D cultures, metanephric organ cultures, and Pkd1RC/RC mice on a C57BL/6 × 129S6/Sv F1 background. Mice were sacrificed at 16 weeks of age. Results PKA-I activation promoted and inhibition prevented ex vivo P-Ser133 CREB expression and cystogenesis. EPAC activation or PKA-II inhibition had no or only minor effects. BLU2864 inhibited in vitro mIMCD3 cystogenesis and ex vivo P-Ser133 CREB expression and cystogenesis. Genetic downregulation of PKA activity and BLU2864 directly and/or indirectly inhibited many pro-proliferative pathways and were both protective in vivo . BLU2864 had no detectable on- or off-target adverse effects. Conclusions PKA-I is the main PKA isozyme promoting cystogenesis. Direct PKA inhibition may be an effective strategy to treat PKD and other conditions where PKA signaling is upregulated. By acting directly on PKA, the inhibition may be more effective than or substantially increase the efficacy of treatments that only affect PKA activity by lowering cAMP.
Prospective Randomized Trial of Continuous Passive Motion Versus Physical Therapy After Arthroscopic Release of Elbow Contracture
O’Driscoll, Shawn W., Liévano, Jorge Rojas , Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Shukla, Dave R. , Olson, Tammy S. , O’Driscoll, Shawn W. , Vaichinger, Anthony M. , Shields, Maegan N. , Fitzsimmons, James S , Sanchez-Sotelo, J. , Morrey, Mark E , Lievano, Jorge Rojas , Shukla, Dave R. , Olson, Tammy S. , Vaichinger, Anthony M. , Shields, Maegan N.

Mayo Clinic

Journal of Bone and Joint Surgery | March 2, 2022 | Volume: 104 | Issue: 5 | Pages: 430-440

10.2106/jbjs.21.00685 | PMID 35234723 Get It

Background: Continuous passive motion (CPM) has been used for decades, but we are not aware of any randomized controlled trials (RCTs) in which CPM has been compared with physical therapy (PT) for rehabilitation following release of elbow contracture. Methods: In this single-blinded, single-center RCT, we randomly assigned patients undergoing arthroscopic release of elbow contracture to a rehabilitation protocol involving either CPM or PT. The primary outcomes were the rate of recovery and the arc of elbow motion (range of motion) at 1 year. The rate of recovery was evaluated by measuring range of motion at 6 weeks and 3 months. The secondary outcomes included other range-of-motion-related outcomes, patient-reported outcome measures (PROMs), flexion strength and endurance, grip strength, and forearm circumference at multiple time points. Results: A total of 24 patients were assigned to receive CPM, and 27 were assigned to receive PT. At 1 year, CPM was superior to PT with regard to the range of motion, with an estimated treatment difference of 9° (95% confidence interval [CI], 3° to 16°; p = 0.007). Similarly, the use of CPM led to a greater range of motion at 6 weeks and 3 months than PT. The percentage of lost motion recovered at 1 year was higher in the CPM group (51%) than in the PT group (36%) (p = 0.01). The probability of restoring a functional range of motion at 1 year was 62% higher in the CPM group than in the PT group (risk ratio for functional range of motion, 1.62; 95% CI, 1.01 to 2.61; p = 0.04). PROM scores were similar in the 2 groups at all time points, except for a difference in the American Shoulder and Elbow Surgeons (ASES) elbow function subscale, in favor of CPM, at 6 weeks. The use of CPM decreased swelling and reduced the loss of flexion strength, flexion endurance, and grip strength on day 3, with no between-group differences thereafter. Conclusions: Among patients undergoing arthroscopic release of elbow contracture, those who received CPM obtained a faster recovery and a greater range of motion at 1 year, with a higher chance of restoration of functional elbow motion than those who underwent routine PT. Level of Evidence: Therapeutic Level I . See Instructions for Authors for a complete description of levels of evidence.
Overwhelming cryptococcosis complicated by cryptococcal endocarditis
Elkhatib, Wiaam , Phillips, Michael B. , Kwon, Joshua Y, Phillips, Michael B , Elkhatib, Wiaam Y , Kwon, Joshua

Mayo Clinic

BMJ Case Reports | March 2, 2022 | Volume: 15 | Issue: 3 | Pages: e247310

10.1136/bcr-2021-247310 | PMID 35236688 Get It

Cryptococcal species endocarditis is infrequently described, carries high mortality and nearly always occurs in immunocompromised states or on prosthetic valves. We report the case of a man in his 70s with multiple recent hospitalisations for pneumonia, hypercalcaemia and septic tank exposure who presented with intermittent fevers, progressive weakness,and worsening encephalopathy, manifested as confusion and word-finding difficulties for 3 weeks. Workup revealed cryptococcal species on blood serum gram stain, native aortic valve endocarditis and meningitis. Cerebrospinal fluid analysis demonstrated lymphocytosis, ultimately found to be secondary to chronic lymphocytic leukaemia. Surgical valve replacement was deemed medically contraindicated and antifungal therapy was initiated. Though poorly understood with very few documented cases, management of cryptococcal endocarditis relies on prompt diagnosis, early surgery when indicated, long-term antifungal therapy and treatment of underlying immunocompromising states where possible.
Novel likely pathogenic SLC20A variant in primary familial brain calcification
Sharma, Rishi , Stitt, Derek

Mayo Clinic

BMJ Case Reports | March 2, 2022 | Volume: 15 | Issue: 3 | Pages: e245909

10.1136/bcr-2021-245909 | PMID 35236675 Get It

A woman in her 30s was referred to our neurology outpatient clinic following an incidental finding of significant bilateral and symmetric basal ganglia, thalamic, cerebellar and subcortical white matter calcification on brain CT and MRI. A diagnosis of asymptomatic primary familial brain calcification (PFBC) was made. Targeted genetic testing revealed a likely pathogenic variant in the SLC20A2 gene, the most common gene in which pathogenic variants have been implicated in PFBC. These findings prompted genetic testing and brain CT of our patient’s asymptomatic 64-year-old father. These tests revealed the same variant in SLC20A2 and similar brain calcification on CT in the patient’s father.